Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | TRHR | P34981 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | NMBR | P28336 | 1/20 | 0.39 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29399601 | 0.79 | SIRT2 (0.49) | SIRT2MDM4TP53NMBR | |
| SCHEMBL28913050 | 0.79 | SIRT2 (0.49) | SIRT2MDM4TP53NMBR | |
| SCHEMBL28913051 | 0.79 | SIRT2 (0.49) | SIRT2MDM4TP53NMBR | |
| SCHEMBL30468161 | 0.79 | SIRT2 (0.55) | SIRT2MDM4TP53NMBR | |
| SCHEMBL29759585 | 0.79 | NMBR (0.47) | SIRT2MDM4TP53HDAC1HDAC2 | |
| SCHEMBL1737899 | 0.79 | MDM4 (0.54) | SIRT2MDM4TP53 | |
| SCHEMBL30433831 | 0.79 | MDM4 (0.54) | SIRT2MDM4TP53 | |
| SCHEMBL13227674 | 0.79 | MDM4 (0.54) | SIRT2MDM4TP53 | |
| SCHEMBL12994493 | 0.79 | MDM4 (0.54) | SIRT2MDM4TP53 | |
| SCHEMBL29368020 | 0.79 | MDM4 (0.54) | SIRT2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016301-A1 | Synthesis of Beta-Arrestin Effectors | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2018-01-18 | — | — | US | disclosed |
| US-20180016301-A1 | Synthesis of Beta-Arrestin Effectors | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2018-01-18 | — | — | US | disclosed |
| US-9611293-B2 | Synthesis of beta-arrestin effectors | TREVENA, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611293-B2 | Synthesis of beta-arrestin effectors | TREVENA, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| WO-2015179349-A2 | SYNTHESIS OF BETA-ARRESTIN EFFECTORS | TREVENA, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20150329593-A1 | Synthesis of Beta-Arrestin Effectors | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2015-11-19 | — | — | US | disclosed |
| US-20150329593-A1 | Synthesis of Beta-Arrestin Effectors | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016301-A1 | Synthesis of Beta-Arrestin Effectors | ARRB1, ADRB1, ADRB3 | REN 666/4885TRHR 614/4885CMA1 3510/4885 |
| US-20150329593-A1 | Synthesis of Beta-Arrestin Effectors | ARRB1, ADRB1, ADRB3 | REN 666/4885TRHR 614/4885CMA1 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.